论文部分内容阅读
目的:探讨重组人促红细胞生成素(rhEPO)对小鼠药理作用的评价方法。方法:煌焦油蓝染色法计数网织红细胞的数量;自动血细胞计数仪分析平均血红蛋白(MCH)的含量。结果:小鼠年龄对结果影响较大,90d以上的小鼠测定结果较稳定;通过比较小鼠肝脏、脾脏及血液的网织红细胞的数量发现,脾脏对红细胞生成素最敏感;红细胞MCH的含量可以间接反应机体内促红细胞生成素的治疗效果。结论:小鼠体内促红细胞生成素的治疗效果可以通过网织红细胞计数和体外MCH的含量来判断。
Objective: To evaluate the pharmacological effects of recombinant human erythropoietin (rhEPO) in mice. Methods: The number of reticulocytes was counted by brilliant tar blue staining and the average hemoglobin (MCH) was analyzed by automatic hemocytometer. Results: The age of mice had a significant effect on the results, and the results were stable in mice over 90 days. By comparing the numbers of reticulocytes in the liver, spleen and blood of mice, the spleen was the most sensitive to erythropoietin. The content of MCH in erythrocytes It can indirectly reflect the therapeutic effect of erythropoietin in the body. Conclusion: The therapeutic effect of erythropoietin in mice can be judged by the reticulocyte count and the content of MCH in vitro.